恩度联合同步调强放疗治疗不能手术局部晚期老年非小细胞肺癌临床观察(1)
摘要：目的 观察和比较恩度联合同步放疗治疗不能手术局部晚期老年非小细胞肺癌的有效性和安全性。方法 2012年10月1日～2015年9月30日，本院 40例经病理证实的符合入选标准的老年局部晚期非小细胞肺癌患者，采用按1∶1比例随机分入试验组和对照组，试验组：20例采用恩度15 mg，1次/d，连续输注14 d，间隔7 d，至少再重复14 d；联合同步调强放疗，放疗采用常规分割，原发灶及纵隔淋巴结剂量DT 60 Gy～66 Gy/30 f～33 f/6～7 w。对照组：20例单独调强放射治疗，剂量、分割方式同试验组。治疗完成后按照实体瘤评价标准( RECIST )评价疗效，记录有效率(response rate， RR)，疾病控制率(disease control rate， DCR)，中位无疾病进展时间(medial progress free survival， mPFS)， 中位生存时间(medial overall survival， mOS)。每周期按照NCI CTC 4.0版标准评价毒性反应。结果 试验组20例患者中， PR 15例，SD 5例，有效率为75.00%(15/20)，疾病控制率100.00%(20/20)；对照组20例患者中，PR16例，SD 2例，有效率為80.00% (16/20)，疾病控制率90.00%(18/20)；两组中位无疾病进展时间(mPFS) (9.4 Mvs6.8 M， P=0.251)；两组主要不良反应多为G 1/2，G 3/4少见，差异无统计学意义。结论 恩度联合放疗治疗老年局部晚期不能手术非小细胞肺癌安全性较好，是综合治疗中的一个重要环节。
, http://www.100md.com
关键词：恩度； 老年； 不可手术；局部晚期非小细胞肺癌； 调强放疗
Abstract：Objective To observe the efficacy and safety of Rh-endostatin combined with concurrent intensity modulated radiation therapy(IMRT) for inoperable elderly local advanced Non-small-cell lung cancer(NSCLC).Methods October 1，2012～2015 year in September 30th，our hospital 40 cases of pathologically confirmed with criteria for elderly patients with locally advanced non-small cell lung cancer patients， according to the proportion of 1：1 were randomly divided into experimental group and control group， experimental group：20 cases with Endostar 15 mg，1/d，continuous infusion of 14 d interval at least 7 d，repeat 14 d；combined with concurrent intensity-modulated radiotherapy with conventional radiotherapy，segmentation，primary tumor and mediastinal lymph nodes of 60 doses of DT Gy～66 Gy/30 f～33 f/6～7 W.The control group：20 cases of individual IMRT dose，segmentation method with the experimental group.After treatment in solid tumors evaluation criteria(RECIST)to evaluate the efficacy of recording efficiency (response rate，RR)，disease control rate(DCR)，median progression free time(medial progress free survival，mPFS)，the median survival time (medial overall，survival，mOS).Each period in accordance with the NCI CTC 4 version of the standard evaluation of toxicity.Results The experimental group of 20 cases，PR 15 cases，SD 5 cases，effective rate was 75.00%(15/20)，the disease control rate was 100.00%(20/20)；20 patients in the control group，PR16 cases， SD 2 cases，efficiency of 80.00% (16/20)，the disease control rate was 90.00%(18/20)；no time to progression in the two group(mPFS)(9.4 Mvs6.8，M，P=0.251)；two groups of adverse reactions for G 1/2，G 3/4 is rare，the difference was not statistically significant.Conclusion Endostar combined with radiotherapy in the treatment of elderly patients with locally advanced non small cell lung cancer with good safety，is an important part of a comprehensive treatment., 百拇医药(陈群 石琴 谢强)
, http://www.100md.com
关键词：恩度； 老年； 不可手术；局部晚期非小细胞肺癌； 调强放疗
Abstract：Objective To observe the efficacy and safety of Rh-endostatin combined with concurrent intensity modulated radiation therapy(IMRT) for inoperable elderly local advanced Non-small-cell lung cancer(NSCLC).Methods October 1，2012～2015 year in September 30th，our hospital 40 cases of pathologically confirmed with criteria for elderly patients with locally advanced non-small cell lung cancer patients， according to the proportion of 1：1 were randomly divided into experimental group and control group， experimental group：20 cases with Endostar 15 mg，1/d，continuous infusion of 14 d interval at least 7 d，repeat 14 d；combined with concurrent intensity-modulated radiotherapy with conventional radiotherapy，segmentation，primary tumor and mediastinal lymph nodes of 60 doses of DT Gy～66 Gy/30 f～33 f/6～7 W.The control group：20 cases of individual IMRT dose，segmentation method with the experimental group.After treatment in solid tumors evaluation criteria(RECIST)to evaluate the efficacy of recording efficiency (response rate，RR)，disease control rate(DCR)，median progression free time(medial progress free survival，mPFS)，the median survival time (medial overall，survival，mOS).Each period in accordance with the NCI CTC 4 version of the standard evaluation of toxicity.Results The experimental group of 20 cases，PR 15 cases，SD 5 cases，effective rate was 75.00%(15/20)，the disease control rate was 100.00%(20/20)；20 patients in the control group，PR16 cases， SD 2 cases，efficiency of 80.00% (16/20)，the disease control rate was 90.00%(18/20)；no time to progression in the two group(mPFS)(9.4 Mvs6.8，M，P=0.251)；two groups of adverse reactions for G 1/2，G 3/4 is rare，the difference was not statistically significant.Conclusion Endostar combined with radiotherapy in the treatment of elderly patients with locally advanced non small cell lung cancer with good safety，is an important part of a comprehensive treatment., 百拇医药(陈群 石琴 谢强)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌